JPMorgan Chase
JPM
$339.72
+1.25%
JPMorgan Chase & Co. is the largest U.S. bank holding company, operating a roughly $5.0 trillion balance sheet across three core segments: Consumer & Community Banking (over 5,000 branches), the Commercial & Investment Bank, and Asset & Wealth Management (over $7.6 trillion in client assets). Its scale, top-ranked investment banking franchise (8.4% global fee share), and fortress balance sheet make it the undisputed bellwether of global banking rather than a niche or disruptive player. The current investor debate centers on whether JPMorgan's record net interest income trajectory — management has guided 2027 NII to roughly $107 billion — can offset a Q3 2026 earnings and revenue miss, a reduced buyback pace, and CEO Jamie Dimon's caution that inflation and asset prices "continue to shift under the surface." Sentiment is further split between long-term bulls who prize the dividend growth and capital discipline and near-term skeptics focused on relative underperformance versus the S&P 500 and the cyclical risk embedded in credit costs.…
JPM
JPMorgan Chase
$339.72
Related headlines
JPM 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on JPMorgan Chase's 12-month outlook, with a consensus price target around $372.57 and implied upside of +9.7% versus the current price.
Average Target
$372.57
0 analysts
Implied Upside
+9.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$312 - $425
Analyst target range
Coverage is deep and constructive: 23 analysts follow JPM with a consensus recommendation of "buy" (mean rating 2.04 on a scale where lower is more bullish) and an average target price of $372.57, implying roughly +9.7% upside from the current $339.72. The consensus leans moderately bullish, supported by recent reiterations — Wells Fargo at Overweight, UBS at Buy, BofA at Buy, Barclays and RBC at Outperform — though HSBC and Truist remain at Hold and Citigroup at Neutral, reflecting valuation caution after the Q3 earnings miss.
The target range of $312.00 to $425.00 is wide — a spread of $113, or about 33% of the current price — signaling meaningful disagreement about the trajectory. The $425 high target likely assumes multiple expansion on accelerating 2027 NII (guided to ~$107 billion), continued investment banking recovery, and sustained buybacks, while the $312 low target prices in margin compression, rising credit costs, and Dimon's macro warnings materializing. Notably, no firm has upgraded recently; actions have been reiterations, and the post-Q3 tone has tilted more cautious, so the wide spread reflects genuine uncertainty rather than strong conviction — investors should weight the average target as a fair-value anchor rather than a near-term catalyst.
Drowning in data?
Find the real signal!
Bulls vs Bears: JPM Investment Factors
The bull case currently rests on stronger hard evidence: 17.94% revenue growth, net margin expansion from 18.71% to 25.65% across three quarters, $107 billion 2027 NII guidance, and a 9.7% analyst target upside all point to durable earnings power. The bear case is primarily valuation- and momentum-driven — 16.07x PE and 2.47x P/B at historical peaks, a Q3 miss, and 7.55 points of YTD underperformance versus SPY — rather than evidence of fundamental deterioration. The single most important tension is whether the 2027 NII trajectory can be delivered without margin compression and rising credit costs; if NII confirms, the premium is earned and the stock re-rates toward $372+, but if the Q3 miss marks the start of margin erosion, multiple compression from peak levels is the dominant risk. On balance, the evidence favors the bulls modestly, but the margin of safety is thin at current prices.
Bullish
- Revenue accelerating at 17.9% YoY: Q2 2026 revenue of $82.46 billion rose 17.94% versus $69.91 billion in Q2 2025, and the sequential path ($69.61B Q4 2025 → $73.66B Q1 2026 → $82.46B Q2 2026) shows acceleration, not deceleration. Both CCB ($19.40B) and CIB ($19.38B) contributed as twin engines, with AWM adding $6.52B.
- Margins expanding sharply quarter-over-quarter: Net margin climbed from 18.71% in Q4 2025 to 22.39% in Q1 2026 to 25.65% in Q2 2026, while gross margin improved from 59.1% to 64.3% to 66.5% over the same quarters. Q2 2026 net income of $21.16 billion was up from $16.49 billion in Q1 and $13.03 billion in Q4 2025.
- 2027 NII guided to ~$107 billion: Management's 2027 net interest income guidance of roughly $107 billion underpins the organic growth case and is the single largest driver of forward EPS. This supports the 17% trailing-to-forward PE compression (16.07x to 13.32x) that implies ~20% earnings expansion toward the $27.53 consensus EPS.
- Fortress capital return and low payout: Q2 2026 alone saw $4.34 billion in dividends and $6.79 billion in buybacks, funded by a $309.8 billion cash position. The 1.86% dividend yield carries a conservative 29.1% payout ratio against a 15.74% ROE, leaving ample room for another dividend raise in 2027.
Bearish
- Valuation at top of historical band: Trailing PE of 16.07x sits near the top of JPM's historical 7.6x–17.4x range, and P/B of 2.47x is essentially at the 2.48x historical peak. The premium to the typical large-bank 11–13x earnings and 1.0–1.5x book leaves little cushion, as the Q3 miss demonstrated.
- Q3 2026 earnings and revenue miss: October's Q3 report lagged both earnings and revenue estimates, and the reduced buyback pace signals capital return is moderating. This is the first concrete crack in the acceleration narrative that drove the stock to $366.50.
- Persistent relative underperformance vs. SPY: JPM trails SPY by 1.74 points over 12 months and a steep 7.55 points YTD (+4.38% vs. +11.93%), with negative relative strength in every window except six months (-3.86 over 1 month, -3.09 over 3 months). The stock is a market laggard despite absolute gains.
- Momentum deceleration and drawdown risk: The stock is down 2.64% over the past month and 0.40% over three months versus a +9.48% six-month gain, and has already suffered a 15.47% max drawdown in the period. At $339.72 it sits 7.3% below the $366.50 high with intermediate support only at $330.
JPM Technical Analysis
JPM is in a broad, choppy uptrend that has lost some altitude: the stock is up 13.79% over the past year but sits at $339.72, roughly 92.7% of its 52-week range of $279.10 to $366.50, about 7.3% below the high and 21.7% above the low. That positioning near the upper end of the range signals residual momentum but also leaves little cushion if sentiment sours, and the 15.47% max drawdown over the period confirms the stock is not a one-way trade. Relative strength tells the same story — JPM trails SPY by 1.74 percentage points over 12 months and by a steep 7.55 points year-to-date (JPM +4.38% vs. SPY +11.93%).
Short-term momentum has clearly decelerated: the stock is down 2.64% over the past month and 0.40% over three months, a sharp contrast to the +9.48% six-month gain, meaning the spring-to-summer rally has stalled into autumn consolidation. This divergence — positive 1-year trend but negative 1-month and 3-month readings — points to a temporary pullback or mean-reversion phase rather than a confirmed reversal, especially since the stock has stabilized recently (up 1.25% on the latest session from $335.53 to $339.72). Relative strength versus the market is negative across every window except six months (-3.86 over 1 month, -3.09 over 3 months, +2.00 over 6 months), confirming JPM is currently a market laggard despite its absolute gains.
Key technical levels are well defined: support sits at the $279.10 52-week low, with intermediate support around the $330 area where the stock has repeatedly found buyers in late September and early October, while resistance is the $366.50 52-week high. A breakout above $366.50 would signal a fresh leg higher and likely require a catalyst such as strong Q4 results or favorable 2027 NII confirmation; a breakdown below $330 would open the door toward the $300–$310 zone and undermine the uptrend. With a beta of 1.015, JPM moves roughly in line with the market — marginally more volatile than SPY — so position sizing should treat it as a market-beta proxy rather than a defensive hedge, and the 3.0 short ratio suggests short interest is moderate and not a major squeeze factor.
Beta
1.01
1.01x market volatility
Max Drawdown
-15.5%
Largest decline past year
52-Week Range
$279-$367
Price range past year
Annual Return
+13.8%
Cumulative gain past year
| Period | JPM Return | S&P 500 |
|---|---|---|
| 1m | -2.6% | +0.2% |
| 3m | -0.4% | +2.9% |
| 6m | +9.5% | +8.4% |
| 1y | +13.8% | +14.9% |
| ytd | +4.4% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JPM Fundamental Analysis
Revenue is growing at a healthy clip: Q2 2026 revenue of $82.46 billion rose 17.94% year-over-year versus $69.91 billion in Q2 2025, and the sequential trajectory ($73.66B in Q1 2026, $69.61B in Q4 2025, $71.90B in Q3 2025) shows acceleration rather than deceleration. Segment data for the quarter shows Consumer & Community Banking at $19.40 billion and the Commercial & Investment Bank at $19.38 billion as the twin engines, with Asset & Wealth Management contributing $6.52 billion and corporate/other items adding $1.48 billion net of a $969 million reconciling charge. This broad-based growth — spanning net interest income and fees — supports the long-term investment case, though the Q3 2026 earnings miss reported in October suggests the pace may be moderating into year-end.
Profitability remains elite for a money-center bank: Q2 2026 net income was $21.16 billion on a 25.65% net margin, with gross margin of 66.5% and operating margin of 33.4%, and net income rose from $16.49 billion in Q1 2026 and $13.03 billion in Q4 2025. The margin trend is expanding — net margin climbed from 18.71% in Q4 2025 to 22.39% in Q1 2026 to 25.65% in Q2 2026, and gross margin improved from 59.1% to 64.3% to 66.5% over the same quarters. TTM figures show a 20.39% net margin, 59.9% gross margin, and 25.95% operating margin, with ROE of 15.74% and ROA of 1.37% — strong absolute returns that reflect JPM's scale advantages, though the Q3 miss and Dimon's inflation warning flag potential margin pressure ahead.
Balance sheet and cash flow metrics require careful interpretation for a bank: debt-to-equity stands at 2.60x, the current ratio is a low 0.52 (typical for a deposit-funded institution), and TTM free cash flow is deeply negative at -$162.5 billion, driven by working-capital swings and securities purchases rather than operating weakness — Q1 2026 operating cash flow was -$211.8 billion versus +$119.7 billion in Q4 2025. Capital return remains robust, with $4.34 billion in dividends and $6.79 billion in buybacks in Q2 2026 alone, funded comfortably by earnings power and a $309.8 billion cash position. The 1.86% dividend yield with a conservative 29.1% payout ratio and 15.74% ROE indicate the bank generates ample internal capital, though the reduced buyback pace noted in Q3 commentary and the negative FCF optics warrant monitoring.
Quarterly Revenue
$82.5B
2026-06
Revenue YoY Growth
+17.9%
YoY Comparison
Gross Margin
66.5%
Latest Quarter
Free Cash Flow
$-162.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JPM Overvalued?
Because JPMorgan is solidly profitable (Q2 2026 net income of $21.16 billion), the PE ratio is the appropriate primary metric: the stock trades at 16.07x trailing earnings versus 13.32x forward earnings, a 17% compression that implies the market expects meaningful EPS growth — consistent with the consensus estimate of $27.53 for the forward period. The PEG ratio of 12.23 is distorted by the unusually low trailing EPS figure in the key-metrics feed and should be treated with caution; the more reliable signal is the trailing-to-forward PE gap, which prices in roughly 20% earnings expansion.
Against the broader financials sector, JPM's 16.07x trailing PE and 2.47x price-to-book sit at a premium to the typical large-bank multiple of roughly 11–13x earnings and 1.0–1.5x book, reflecting its superior 15.74% ROE, 20.39% net margin, and dominant franchise position. The 3.20x price-to-sales and 18.35x EV/EBITDA are rich for a bank, while the 1.86% dividend yield is modest relative to peers but backed by a low 29.1% payout ratio. The premium is defensible on quality grounds — JPM's returns on capital and earnings stability are best-in-class — but leaves limited room for disappointment, as the Q3 miss demonstrated.
Historically, JPM's PE has ranged from roughly 7.6x (Q2 2023) to 17.4x (Q4 2025), and the current 16.07x sits near the upper end of that band, while the 2.47x P/B compares to a historical range of about 1.07x to 2.48x — essentially at the top. This suggests the market is pricing in optimistic expectations for sustained NII growth and capital returns, leaving the stock vulnerable to multiple compression if earnings momentum fades. The current valuation is not a value opportunity; it is a quality-at-a-premium proposition that requires continued execution.
PE
16.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings quality and capital flexibility. The Q3 2026 earnings and revenue miss, combined with a reduced buyback pace, shows that the record NII trajectory is not immune to moderation, and Dimon's inflation warning flags potential margin pressure ahead. TTM free cash flow is deeply negative at -$162.5 billion (Q1 2026 operating cash flow of -$211.8 billion versus +$119.7 billion in Q4 2025), driven by working-capital swings and securities purchases; while typical for a bank, it limits the optical cushion. A current ratio of 0.52 and debt-to-equity of 2.60x are normal for a deposit-funded institution but leave the balance sheet sensitive to funding-cost shocks, and revenue concentration in CCB ($19.40B) and CIB ($19.38B) means a credit or capital-markets downturn hits both engines simultaneously.
Market and competitive risks are dominated by valuation compression. At 16.07x trailing earnings and 2.47x book — near the top of the 7.6x–17.4x and 1.07x–2.48x historical ranges — JPM trades at a premium to the 11–13x and 1.0–1.5x typical large-bank multiples, so any earnings disappointment is amplified by multiple contraction. The stock already trails SPY by 7.55 points YTD and 1.74 points over 12 months, with negative relative strength in three of four windows, suggesting capital rotation away from money-center banks. Beta of 1.015 means JPM offers essentially no defensive offset in a market selloff, and the investment banking recovery appears concentrated among advisory-heavy firms like Jefferies and Morgan Stanley while universal banks lag, per recent industry commentary.
In a worst-case scenario, a credit-cost upcycle colliding with NII guidance disappointment would trigger both EPS cuts and multiple compression from peak levels. The stock could retrace to its $279.10 52-week low — a decline of roughly 17.8% from $339.72 — and the analyst low target of $312.00 implies about 8.2% downside as a milder bear marker. A break below the $330 intermediate support would open the $300–$310 zone, consistent with the 15.47% max drawdown already experienced this period; a full re-test of the low would represent a loss of approximately $60 per share from current levels.